Hematologic Malignancies

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

By

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

Treatment Outcomes Were Unchanged by Brentuximab Vedotin (BV)-induced Peripheral Neuropathy

By

Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

Pembrolizumab Active in Refractory NK/T-cell Lymphoma

By

PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.

BBD Regimen Efficacious as First-line Therapy for Myeloma

BBD Regimen Efficacious as First-line Therapy for Myeloma

By

Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

Managing Adverse Effects From Oral Kinase Inhibitors in Patients With Hematologic Cancers

By

Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

By

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

Anxiety, Distress Common Among Patients With BCR-ABL-negative MPNs

By

In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

By

Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

By

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

Data Confirm Auto-HCT as Standard Approach for Myeloma in Young Patients

Data Confirm Auto-HCT as Standard Approach for Myeloma in Young Patients

By

A pooled analysis confirms the role of upfront autologous HCT as the standard approach for all young patients with multiple myeloma.

What Is The Optimal Sequencing of Novel Agents for CLL?

What Is The Optimal Sequencing of Novel Agents for CLL?

By

Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.

VT Maintenance Improves PFS vs Thalidomide or Interferon in Myeloma

VT Maintenance Improves PFS vs Thalidomide or Interferon in Myeloma

By

In this study, maintenance therapy with bortezomib plus thalidomide was compared with thalidomide alone or interferon alfa-2b alone in patients with newly diagnosed symptomatic multiple myeloma. Study findings demonstrate an impact on progression-free survival.

Pretransplant Depression Associated With Worse Overall Survival

Pretransplant Depression Associated With Worse Overall Survival

By

An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.

Nilotinib for CML Associated With Improved Quality of Life

Nilotinib for CML Associated With Improved Quality of Life

By

Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.

Adding Pioglitazone to Imatinib May Improve Response in CML

Adding Pioglitazone to Imatinib May Improve Response in CML

By

Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

By

Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.

Racial Disparities Persist in Myeloma Treatment Use

Racial Disparities Persist in Myeloma Treatment Use

By

Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

By

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

By

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

By

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

O-DHAP and R-DHAP Equivalent As Salvage Therapy for R/R DLBCL

By

Researchers sought to compare the efficacy of O-DHAP with R-DHAP as salvage treatment, followed by autologous hematopoietic cell transplantation.

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

By

A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.

Beta-blockers May Improve Survival in Multiple Myeloma

Beta-blockers May Improve Survival in Multiple Myeloma

By

Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

By

Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

By

The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

By

A panel of International Myeloma Working Group members  presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

By

In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

By

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

By

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs